Cisplatin Every 3 Weeks Versus Weekly With Definitive Concurrent Radiotherapy for Squamous Cell Carcinoma of the Head and Neck

BACKGROUND: Concurrent chemoradiotherapy is an established component of the nonoperative management of locally advanced head and neck squamous cell carcinoma (HNSCC), but the standard dose of 100 mg/m(2) cisplatin every 3 weeks is associated with clinically significant toxicity. Interest in a more t...

詳細記述

保存先:
書誌詳細
出版年:J Natl Cancer Inst
主要な著者: Bauml, Joshua M, Vinnakota, Ravi, Anna Park, Yeun-Hee, Bates, Susan E, Fojo, Tito, Aggarwal, Charu, Limaye, Sewanti, Damjanov, Nevena, Di Stefano, Jessica, Ciunci, Christine, Genden, Eric M, Wisnivesky, Juan P, Ferrandino, Rocco, Mamtani, Ronac, Langer, Corey J, Cohen, Roger B, Sigel, Keith
フォーマット: Artigo
言語:Inglês
出版事項: Oxford University Press 2018
主題:
Articles
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6510226/
https://ncbi.nlm.nih.gov/pubmed/30239887
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jnci/djy133
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料